Navigation Links
Investigational ovarian cancer drug shows promise against platinum resistant disease
Date:10/9/2010

A drug being developed as a treatment for ovarian cancer has shown single agent activity with durable disease control in some patients in a Phase-II clinical trial, an international research group has reported.

Dr Ursula Matulonis from Dana-Farber Cancer Institute in the USA reported the results of the single-agent trial of the drug, called MLN8237, in a poster at the 35th Congress of the European Society for Medical Oncology (ESMO).

MLN8237 selectively inhibits an enzyme known as Aurora A kinase, which is a member of a family of kinase enzymes involved in normal cell division. Researchers have found that Aurora A kinase is over-expressed in some cancer cells, leading to growth of cancers.

"In epithelial ovarian cancer, Aurora A kinase has been reported to be frequently upregulated or overexpressed, and associated with worse clinical outcome," Dr Matulonis said. "This is why an effective Aurora A Kinase inhibitor is a potential new therapy to be used alone or in combination with other standard agents such as paclitaxel."

In addition to ovarian cancer, the Aurora A kinase gene is amplified or overexpressed, or both, in other cancers including colon, breast, pancreatic, and bladder cancers, as well as certain lymphomas, leukemias and myeloma.

Unlike other aurora kinase inhibitors currently being studied, MLN8237 selectively targets aurora A Kinase and can be administered orally, Dr Matulonis said.

In the current study, sponsored by Millennium Pharmaceuticals, American, French, Italian and Polish researchers treated 31 patients whose cancer was resistant or refractory to platinum-based chemotherapy and who had tried at least three other therapies. Twenty-five patients had ovarian cancer, 5 had primary peritoneal cancer, and one had Fallopian tube carcinoma.

"The patients enrolled to this study all had progression after platinum-containing regimens which is the mainstay of ovarian cancer treatment," Dr Matulonis said. "Patients with 'platinum resistant' recurrent ovarian cancer represent a large unmet medical need."

The patients received MLN8237 in 21-day cycles: seven days of twice-daily 50mg treatment, followed by a 14-day break. Three patients had a partial response to the treatment, and 5 had stable disease that was sustained for at least four 21-week cycles, the researchers report.

"The most important finding from this study was the fact that MLN8237 demonstrates single-agent activity in ovarian cancer with encouraging durable disease control in some patients," Dr Matulonis said.

Several patients have remained on the study drug for over 12 months, she noted. "I personally have a patient on this current study who has been on MLN8237 for now more than 12 months. She is doing remarkably well."

The fact that multiple patients had stable disease or response suggests that future development of MLN8237 in combination with other active agents may be a promising avenue to investigate, the researchers said.

"These durable responses are encouraging since all of the patients enrolled on this study have failed platinum. Because of the other durable responses reported in other MLN8237 studies, this all helps support the prediction that this is a new mechanism to fight cancer, and the MLN8237 drug does not appear to share mechanisms for resistance to other available drugs."

The researchers noted that the drug had various toxicities. The most common serious toxicities included neutropenia, stomatitis, leucopenia, thrombocytopenia and fatigue, which were generally reversible during the 14-day break in treatment. Five patients discontinued due to adverse events.

The fact that the drug has shown some efficacy in treating drug-resistant ovarian cancer "is worth exploring further," noted Professor Stan Kaye, Professor of Medical Oncology at the Royal Marsden Hospital.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. Investigational immune intervention slows brain shrinkage in Alzheimers patients
2. Initial trials on new ovarian cancer tests exhibit extremely high accuracy
3. TGen finds protein inhibitor revives chemotherapy for ovarian patients
4. Ovarian transplantation restores fertility to old mice and also lengthens their lives
5. Flaxseed-fed chickens shed light on ovarian cancer
6. Spirit of ovarian cancer advocate keeps fundraising drive on track
7. The pill for ovarian cysts
8. Dietary factors influence ovarian cancer survival rates
9. Disarming specialized stem cells might combat deadly ovarian cancer
10. Assessing lead time of selected ovarian cancer biomarkers
11. FDA approved leukemia drugs shows promise in ovarian cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
(Date:11/30/2016)... Nov. 30, 2016  higi SH llc (higi) ... initiative targeting national brands, industry thought-leaders and celebrity ... respective audiences for taking steps to live healthier, ... in 2012, higi has built the largest self-screening ... 38 million people who have conducted over 185 ...
(Date:11/29/2016)... , Nov. 29, 2016   ... identification and object recognition technologies, today released ... for fingerprint recognition solutions that run on ... fingerprint template using less than 128KB of ... compact devices that have limited on-board resources, ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... ... December 06, 2016 , ... Clinical Supplies ... has acquired the assets of Theorem Clinical Research - Clinical Supplies ("TCS"). ... trial drug packaging, labeling, storage, reconciliation, and distribution for pharmaceutical trials across ...
(Date:12/6/2016)... 6, 2016  The Texas Medical Center ... (HISA) today announced the establishment of a new ... Australia and the Texas Medical ... HISA and the Texas Medical Center, with ... create a global health innovation ecosystem where emerging technologies ...
(Date:12/5/2016)... , Dec 5, 2016 Research and ... "Biomarkers - Technologies, Markets and Companies" to their offering. ... , , ... their discovery using various -omics technologies such as proteomics and metabolomics. ... new tests are also based on biomarker. Currently the ...
(Date:12/5/2016)... 5, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or ... Data and Safety Monitoring Board (DSMB) for the ... disease (CVD) patients has completed a second planned ... continue as planned without any modifications. The DSMB ... safety or efficacy concerns were identified. The DSMB ...
Breaking Biology Technology: